About Aptahem

Sponsor retains sole responsibility for content.

Aptahem AB is a Swedish-based biotechnology company that develops innovative aptamer-based drugs targeting inflammation and coagulation for the treatment of life-threatening conditions. The portfolio under development consists of multifunctional aptamer (synthetic constructed nucleic acid polymers) drug candidates with anti-coagulant, immunostimulant and anti-inflammatory properties. The company...

Aptahem AB is a Swedish-based biotechnology company that develops innovative aptamer-based drugs targeting inflammation and coagulation for the treatment of life-threatening conditions. The portfolio under development consists of multifunctional aptamer (synthetic constructed nucleic acid polymers) drug candidates with anti-coagulant, immunostimulant and anti-inflammatory properties. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by the severe inflammatory response that leads to organ and tissue damage in sepsis patients. The multi-functional profile of Apta-1 has shown to improve the survival of animals in a dose dependent manner in a lethal sepsis model in an unprecedented way. Aptahem is also investigating a second candidate, Apta-2, for the treatment of inflammatory diseases. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Contact Aptahem

Phone Number
+46 76 6333699

More About Aptahem

Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Infectious
  • Inflammation
  • Metabolic
  • Ophthalmics
Technologies
  • Antimicrobial
  • Diagnostics
  • Drug delivery
  • Regenerative medicine
Company Type
  • Biotechnology – R&D services
State of Ownership
  • Private
Sponsorship Group
  • Networker